Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xuefeng Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7148-846X; OpenAlex author ID A5065249628. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 6 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper

Papers 17

  1. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  2. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Co-author DOI 10.1007/s10620-022-07671-w↗
  3. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Co-author DOI 10.21037/atm-22-1946↗
  4. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis. Co-author DOI 10.3389/fonc.2022.789351↗
  5. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  6. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Co-author DOI 10.1007/s10147-020-01782-y↗
  7. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  8. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  9. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111543↗
  10. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s40880-019-0410-8↗
  11. Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Last author DOI 10.2147/ott.s176101↗
  12. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Co-author DOI 10.7150/jca.35856↗
  13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  14. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Co-author DOI 10.2217/fon-2017-0380↗
  15. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Co-author DOI 10.7150/jca.20917↗
  16. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. First author DOI 10.1097/mpa.0000000000000501↗
  17. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. Co-author DOI 10.3892/ol.2014.2628↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dansong Wang · 15 shared papers, 2015–2024 · strength 1.68
  2. Tiantao Kuang · 15 shared papers, 2015–2024 · strength 1.68
  3. Dayong Jin · 12 shared papers, 2015–2024 · strength 1.32
  4. Wenchuan Wu · 12 shared papers, 2017–2024 · strength 1.28
  5. Yefei Rong · 8 shared papers, 2015–2024 · strength 0.92
  6. Wenhui Lou · 7 shared papers, 2018–2022 · strength 0.76
  7. Wenhui Lou · 7 shared papers, 2015–2024 · strength 0.68
  8. Jianang Li · 5 shared papers, 2016–2023 · strength 0.48
  9. Ning Pu · 6 shared papers, 2017–2019 · strength 0.48
  10. Yaolin Xu · 3 shared papers, 2021–2024 · strength 0.45
  11. Weilin Mao · 3 shared papers, 2019–2023 · strength 0.44
  12. Wenhui Lou · 3 shared papers, 2016–2023 · strength 0.41
  13. Yueming Zhang · 2 shared papers, 2021–2022 · strength 0.30
  14. Yuan Fang · 3 shared papers, 2019 · strength 0.27
  15. Hanlin Yin · 3 shared papers, 2018–2019 · strength 0.25
  16. Lei Zhang · 2 shared papers, 2015–2022 · strength 0.22
  17. Lei Zhang · 1 shared paper, 2023 · strength 0.19
  18. Wentao Zhou · 2 shared papers, 2019 · strength 0.19
  19. Zhe Wang · 1 shared paper, 2022 · strength 0.16
  20. Lie Yao · 1 shared paper, 2024 · strength 0.16
  21. Tianshu Liu · 1 shared paper, 2024 · strength 0.16
  22. Yuan Ji Ma · 1 shared paper, 2024 · strength 0.16
  23. Xi Guo · 1 shared paper, 2024 · strength 0.16
  24. Lili Wu · 1 shared paper, 2024 · strength 0.16
  25. Wenquan Wang · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.